Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Topivert Pharma Limited logo — company profile

Topivert Pharma Limited

Founded 2011 United Kingdom London, United Kingdom 3 employees Series A Biotechnology, Health Care

General Information

Company Name Topivert Pharma Limited
Founded Year 2011
Location United Kingdom London, United Kingdom
Employees 3
Industries Biotechnology, Health Care
Funding Stage Series A
Social

BounceWatch is an independent company data service, not affiliated with Topivert Pharma Limited. To contact Topivert Pharma Limited, visit topivert.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

About Topivert Pharma Limited

TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye. The lead GI programme TOP1288 is currently in a Phase IIa proof of concept study in ulcerative colitis. A Phase I/II study with TOP1630 for dry eye syndrome will commence in the US in early 2017.

No funding data available for Topivert Pharma Limited yet.

Topivert Pharma Limited Alternatives & Competitors

Topivert Pharma Limited vs
Sublimity Therapeutics
Sublimity Therapeutics Ireland

Sublimity Therapeutics is a clinical-stage biotechnology company dedicated to identifying and develo...

Series B
9 employees
Biotechnology, Health Care
Topivert Pharma Limited vs
Entero Therapeutics (Nasdaq: ENTO)
Entero Therapeutics (Nasdaq: ENTO) United States

A biopharma company focused on the development of targeted, non-systemic therapies for gastrointesti...

Post-IPO Equity
12 employees
Biotechnology, Health Care
Topivert Pharma Limited vs
Abivax
Abivax France

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the...

Post-IPO Debt
90 employees
Biotechnology, Health Care

FAQ About Topivert Pharma Limited

TopiVert is a clinical-stage biotechnology company developing next-generation, Narrow Spectrum Kinase Inhibitors (NSKIs) as novel, non-systemic medicines for the treatment of chronic inflammatory diseases of the gastrointestinal (GI) tract and the eye. The lead GI programme TOP1288 is currently in a...
Topivert Pharma Limited was founded in 2011.
Topivert Pharma Limited is headquartered in London, United Kingdom.
Topivert Pharma Limited operates in Biotechnology and Health Care.
Topivert Pharma Limited has approximately 3 employees.
Top alternatives and competitors to Topivert Pharma Limited include Sublimity Therapeutics, Entero Therapeutics (Nasdaq: ENTO), Abivax, ZaBeCor Pharmaceuticals, Cloudbreak Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Topivert Pharma Limited and Sublimity Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Topivert Pharma Limited, https://bouncewatch.com/company/topivert-pharma-limited, updated 3 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes